Lymphadenectomy Benefits Small Cell Carcinoma of Ovary: A Population-Based Analysis
Open Access
- 16 October 2022
- journal article
- research article
- Published by MDPI AG in Current Oncology
- Vol. 29 (10) , 7802-7815
Abstract
Small cell carcinoma of the ovary (SCCO) is a rare type of ovarian cancer with high aggressiveness. The optimal treatment modality remains elusive. This study aims to comprehensively investigate the survival impact of clinical characteristics and treatments including lymphadenectomy in SCCO. A retrospective cohort study was performed and included patients from the Surveillance, Epidemiology, and End Results (SEER) database. Data collected included demographics, therapeutic details, and pathologic characteristics. Propensity-score matching analysis (PSM) was carried out to balance baseline variables between SCCO and non-SCCO. Cox regression, Kaplan–Meier, and stratified analyses were conducted before and after PSM. After filtering, 80 records on SCCO and 39,662 records on non-SSCO were obtained. Patients with SCCO were more prone to present unilateral tumor (57.6% and 85.0%, p < 0.001), larger tumor size (>15 cm: 9.5% and 32.5%; 10–15 cm: 13.2% vs. 22.5%, p < 0.001), younger age (59.1 ± 14.91 vs. 37.2 ± 19.05; p < 0.001), single status (17.0% vs. 45.0%; p < 0.001), single malignant tumor in a lifetime (76.1% vs. 87.5%; p = 0.0244), and pathologic grade IV diseases (14.5% vs. 40.0%; p < 0.001) compared with non-SCCO. After balancing the baseline clinical characteristics with a 1:4 ratio PSM, a total of matched 72 patients with SCCO and 254 patients with non-SCCO were identified. The survival rate of SCCO was distinctly inferior to non-SCCO, particularly in FIGO I, II, and III stages. Lymphadenectomy was performed in 37 (51.39%) SCCO patients, of whom 12 (32.43%) were found to have pathologically positive lymph nodes. Lymphadenectomy was linked to favorable overall survival in SCCO, particularly in the advanced stage, and was also an independent prognostic factor, whereas lymphadenectomy did not reveal an edge in matched non-SCCO. There was a pronounced survival benefit for SCCO when at least 10 or more nodes were resected. Lymphadenectomy in a non-stage-dependent way should be considered and deserves further clinical validation to promote the overall survival in SCCO.Keywords
Funding Information
- Shanghai Municipal Hospital Development Center (SHDC12020108, 2020YJZX0202)
- Shanghai Municipal Health Commission (SHDC12020108, 2020YJZX0202)
This publication has 26 references indexed in Scilit:
- The histone methyltransferaseEZH2is a therapeutic target in small cell carcinoma of the ovary, hypercalcaemic typeThe Journal of Pathology, 2017
- A novel nomogram based on LODDS to predict the prognosis of epithelial ovarian cancerOncotarget, 2016
- Small-Cell Carcinoma of the Ovary of Hypercalcemic Type (Malignant Rhabdoid Tumor of the Ovary)Surgical Pathology Clinics, 2016
- Germline and somatic SMARCA4 mutations characterize small cell carcinoma of the ovary, hypercalcemic typeNature Genetics, 2014
- Small cell carcinoma of the ovary, hypercalcemic type, displays frequent inactivating germline and somatic mutations in SMARCA4Nature Genetics, 2014
- Recurrent SMARCA4 mutations in small cell carcinoma of the ovaryNature Genetics, 2014
- Small Cell Ovarian Carcinomas - Characterisation of Two Rare Tumor EntitiesGeburtshilfe und Frauenheilkunde, 2013
- Small cell of the ovary, hypercalcemic type—Analysis of combined experience and recommendation for management. A GCIG studyGynecologic Oncology, 2006
- Small Cell Carcinoma of the Ovary, Hypercalcemic TypeAmerican Journal of Surgical Pathology, 1994
- Primary Ovarian Small Cell Carcinoma of Pulmonary TypeAmerican Journal of Surgical Pathology, 1992